Review



archer fusionplex sarcoma v2 panel  (Integrated DNA Technologies)


Bioz Verified Symbol Integrated DNA Technologies is a verified supplier
Bioz Manufacturer Symbol Integrated DNA Technologies manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Integrated DNA Technologies archer fusionplex sarcoma v2 panel
    Archer Fusionplex Sarcoma V2 Panel, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 99/100, based on 291 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sarcomas/Archer+FUSIONPlex+Sarcoma+v2+panel/custom%40fusionplex-sarcoma-v2-panel%4042791032
    Average 99 stars, based on 291 article reviews
    archer fusionplex sarcoma v2 panel - by Bioz Stars, 2026-11
    99/100 stars

    Images

    Related Articles

    Methylation:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Next-Generation Sequencing:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    DNA Methylation Assay:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Generated:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    RNA Sequencing:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Sequencing:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Staining:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Multiplex Assay:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Immunohistochemical staining:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Ligation:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Restriction Assay:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Synthesized:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Fluorescence:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Fluorescence In Situ Hybridization:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Hybridization:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    In Situ:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    In Situ Hybridization:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Translocation Assay:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi

    Reverse Transcription Polymerase Chain Reaction:

    Article Title: Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.
    Article Snippet: tiplex PCRbased targeted RNA sequencing. Formalinfixed, paraffinembedded tumor samples from 11 surgically resected pulmonary spindle cell tumors, excluding metastatic sarcomas, were analyzed using the FusionPlex Sarcoma panel supplemented with custom primers for RET, NTRK1, NTRK2, and NRG1. Two tumors (18.2%) harbored ALK fusions, identified as PPFIBP1::ALK and SYCL3::ALK. Both tumors showed positi



    Similar Products

    99
    Integrated DNA Technologies archer fusionplex sarcoma v2 panel
    Archer Fusionplex Sarcoma V2 Panel, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sarcomas/Archer+FUSIONPlex+Sarcoma+v2+panel/custom%40fusionplex-sarcoma-v2-panel%4042791032
    Average 99 stars, based on 1 article reviews
    archer fusionplex sarcoma v2 panel - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    96
    ATCC synovial sarcoma cell line sw 982
    Synovial Sarcoma Cell Line Sw 982, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sarcomas/SW+982/10__1016_slash_j__ces__2026__125283-161-6-11
    Average 96 stars, based on 1 article reviews
    synovial sarcoma cell line sw 982 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    ATCC ewing sarcoma cell lines
    Three EWSR1::FLI1 fusion protein isoforms were expressed in the <t>Ewing</t> <t>sarcoma</t> <t>cell</t> <t>lines</t> with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.
    Ewing Sarcoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sarcomas/SK-ES-1/pmc13231080-570-1-23
    Average 95 stars, based on 1 article reviews
    ewing sarcoma cell lines - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    ATCC uterine sarcoma messa
    Three EWSR1::FLI1 fusion protein isoforms were expressed in the <t>Ewing</t> <t>sarcoma</t> <t>cell</t> <t>lines</t> with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.
    Uterine Sarcoma Messa, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sarcomas/MES-SA/pm42284392-241-12-28
    Average 96 stars, based on 1 article reviews
    uterine sarcoma messa - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    86
    Sanofi sarcoma
    Three EWSR1::FLI1 fusion protein isoforms were expressed in the <t>Ewing</t> <t>sarcoma</t> <t>cell</t> <t>lines</t> with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.
    Sarcoma, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sarcomas/sarcoma/pmc13268934-27-11-4
    Average 86 stars, based on 1 article reviews
    sarcoma - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    Image Search Results


    Three EWSR1::FLI1 fusion protein isoforms were expressed in the Ewing sarcoma cell lines with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.

    Journal: iScience

    Article Title: FusionTarget: Computational framework for drug repurposing against modeled fusion protein structures from genomic breakpoints

    doi: 10.1016/j.isci.2026.116076

    Figure Lengend Snippet: Three EWSR1::FLI1 fusion protein isoforms were expressed in the Ewing sarcoma cell lines with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.

    Article Snippet: The Ewing sarcoma cell lines (RD-ES and SK-ES-1) containing the EWS-FLI1 fusion protein employed in this project so far were purchased from the American Tissue Culture Collection (ATCC).

    Techniques: Binding Assay

    Ewing sarcoma cell line sensitivity validation of the predicted EWSR1::FLI1 inhibitors (A) Previous studies of seven drugs in sarcoma. (B) IC 50 values for each cell line/drug combination. (C) Percent viability graphs depicting the IC 50 for each cell line drug combination at a log 10 [concentration]. Error bars have been removed for clarity. (D) Cell proliferation assay to assess the sensitivity of Ewing sarcoma cells to EWSR1::FLI1-predicted inhibitors over a 96-h time course, compared with rhabdomyosarcoma cells treated at the highest Ewing sarcoma IC 50 concentration. (E) Significant differential binding scores between normalized ones targeting fusion proteins and normalized ones targeting the wild-type FLI1 across six EWSR1::FLI1 fusions. (F) 200 nsec period MDS comparison of trifluridin, valruvicin, and the most studied small molecule TK-216 between EWSR1::FLI1 (587AA) fusion protein and FLI1 WT protein. (G) Top: mRNA level of NROB1 was examined in EWSR1::FLI1 positive and negative fusion cells. Bottom: mRNA level of TGFBR2 was examined in EWSR1::FLI1 positive and negative fusion cells. For all bar graphs, results are shown for statistical analyses done in three replicates; ∗, p < 0.05; ∗∗, p < 0.01; and ∗∗∗, p < 0.001.

    Journal: iScience

    Article Title: FusionTarget: Computational framework for drug repurposing against modeled fusion protein structures from genomic breakpoints

    doi: 10.1016/j.isci.2026.116076

    Figure Lengend Snippet: Ewing sarcoma cell line sensitivity validation of the predicted EWSR1::FLI1 inhibitors (A) Previous studies of seven drugs in sarcoma. (B) IC 50 values for each cell line/drug combination. (C) Percent viability graphs depicting the IC 50 for each cell line drug combination at a log 10 [concentration]. Error bars have been removed for clarity. (D) Cell proliferation assay to assess the sensitivity of Ewing sarcoma cells to EWSR1::FLI1-predicted inhibitors over a 96-h time course, compared with rhabdomyosarcoma cells treated at the highest Ewing sarcoma IC 50 concentration. (E) Significant differential binding scores between normalized ones targeting fusion proteins and normalized ones targeting the wild-type FLI1 across six EWSR1::FLI1 fusions. (F) 200 nsec period MDS comparison of trifluridin, valruvicin, and the most studied small molecule TK-216 between EWSR1::FLI1 (587AA) fusion protein and FLI1 WT protein. (G) Top: mRNA level of NROB1 was examined in EWSR1::FLI1 positive and negative fusion cells. Bottom: mRNA level of TGFBR2 was examined in EWSR1::FLI1 positive and negative fusion cells. For all bar graphs, results are shown for statistical analyses done in three replicates; ∗, p < 0.05; ∗∗, p < 0.01; and ∗∗∗, p < 0.001.

    Article Snippet: The Ewing sarcoma cell lines (RD-ES and SK-ES-1) containing the EWS-FLI1 fusion protein employed in this project so far were purchased from the American Tissue Culture Collection (ATCC).

    Techniques: Biomarker Discovery, Concentration Assay, Proliferation Assay, Binding Assay, Comparison